{"id":"W4284989340","doi":"10.1093/jjco/hyac105","title":"A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20)","year":2022,"lang":"en","type":"article","venue":"Japanese Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cytodiagnostics (Canada)","funders":"Japan Agency for Medical Research and Development","keywords":"Gemtuzumab ozogamicin; Medicine; Minimal residual disease; Internal medicine; Myeloid leukemia; Induction chemotherapy; Oncology; Acute promyelocytic leukemia; Hematopoietic stem cell transplantation; Clinical endpoint; Leukemia; Transplantation; Clinical trial; Calicheamicin; Chemotherapy; Stem cell; CD33; CD34","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02405782,0.00028818,0.002843134,0.0004720601,0.0002506771,0.00001459772,0.0002712698,0.0002218824,0.00001085196],"category_scores_gemma":[0.0121731,0.0002020918,0.000394003,0.0004910458,0.0005306117,0.0002093117,0.00006641186,0.00136713,1.066004e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006453663,"about_ca_system_score_gemma":0.005178561,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001550698,"about_ca_topic_score_gemma":0.00009487608,"domain_scores_codex":[0.9883233,0.004311536,0.00536364,0.0005684533,0.001112476,0.000320618],"domain_scores_gemma":[0.9773333,0.01217086,0.007887349,0.0003628075,0.001941446,0.000304205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8394089,0.02158566,0.08747549,0.00004779447,0.001242956,0.00001467848,0.001442914,0.001099678,0.0007324095,0.000004298656,0.00001562884,0.0469296],"study_design_scores_gemma":[0.5952582,0.1969469,0.185894,0.00006934422,0.001496998,0.00002102324,0.001438066,0.01864087,0.00008045648,0.0000372915,0.000001296518,0.0001154828],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850086,0.00001059184,0.00101653,0.0006715323,0.0001619711,0.01301507,0.0001016476,0.00001000557,0.000004051169],"genre_scores_gemma":[0.9897555,0.00003134722,0.009056161,0.00009915028,0.0003233977,0.000469987,0.0002086775,0.00004679673,0.000008984399],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2441507,"threshold_uncertainty_score":0.9961478,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05386085830409168,"score_gpt":0.4327060525568209,"score_spread":0.3788451942527292,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}